Growth modulation of human prostatic cancer cells by interleukin-1 and interleukin-1 receptor antagonist.
The effects of interleukin-1 (IL-1 alpha or IL 1 beta) on androgen-dependent LNCaP and androgen-independent JCA-1 human prostatic cancer cell proliferation were investigated. IL-1 alpha or IL-1 beta induced a dose dependent growth reduction by 50-80% as determined by cell cycle phase distribution, cell number and clonal growth in short and long term cultures. IL-1 negated the androgen growth effect on equal molar basis but the androgen receptors were not blocked by IL-1. The presence of intracellular IL-1 receptors was detected by flow cytometry and the IL-1 mediated growth reduction could be blocked with a 500 fold excess of the IL-1 receptor antagonist (hIL-1ra), revealing a growth control involving IL-1, HIL-1ra, androgen and their receptors.
Hsieh
T C
TC
Department of Medicine, New York Medical College, Valhalla 10595, USA.
Chiao
J W
JW
D002455:Cell Division / Q000187:drug effects*; D013196:Dihydrotestosterone / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000494:pharmacology*; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology*; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D012795:Sialoglycoproteins / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D017472:Receptors, Interleukin-1; D012795:Sialoglycoproteins; D013196:Dihydrotestosterone